Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections by Nijnik, A & Hancock, REW
REVIEW
Host defence peptides: antimicrobial and
immunomodulatory activity and potential applications
for tackling antibiotic-resistant infections
A Nijnik and REW Hancock
Department of Microbiology and Immunology, Centre for Microbial Diseases and Immunity Research, University of British Columbia,
Vancouver, Canada
Correspondence
Professor REW Hancock,
Department of Microbiology and
Immunology, Centre for Microbial
Diseases and Immunity Research,
2259 Lower Mall Research Station,
University of British Columbia,
Vancouver, Canada V6T 1Z4.
E-mail: bob@cmdr.ubc.ca
Received 16 June 2008
Revised 21 August 2008
Accepted 21 October 2008
The rapidly increasing incidence of multidrug-resistant infections and the alarmingly low rate of
discovery of conventional antibiotics create an urgent need for alternative strategies to treat
bacterial infections. Host defence peptides are short cationic molecules produced by the
immune systems of most multicellular organisms; they are a class of compounds being actively
researched. In this review, we provide an overview of the antimicrobial and immunomodulatory
activities of natural host defence peptides, and discuss strategies for creating artificial derivatives
with improved biological and pharmacological properties, issues of microbial resistance, and
challenges associated with their adaptation for clinical use.
Introduction
Host defence peptides (HDPs) are an evolutionarily ancient
component of the innate immune system of most
multicellular organisms.
1 They exhibit a wide range of
biological activities from direct killing of invading pathogens
to modulation of immunity and other biological responses
of the host. In this article, we will refer to the overlapping
classes of peptides with these activities as antimicrobial
and immunomodulatory, respectively. Despite the enormous
diversity in their sequences and structures, most HDPs
share the following features: positive charge, high content
of hydrophobic residues, and amphipathic fold.
2
The structural diversity of natural peptides provides an
excellent starting point for the production of artificial
peptides and derivatives with more potent and desirable
biological activities, for clinical and commercial
applications.
3
The diversity of host defence peptides
Two major families of naturally occurring HDPs have been
distinguished: defensins and cathelicidins (Table 1). Defen-
sins are cationic amphipathic peptides with an average
length of 30 residues and a triple-stranded antiparallel
b-sheet structure, stabilised by three disulphide bonds.
4
Defensins are further subdivided into three subfamilies of
a, b, and y defensins, based on the pattern of disulphide-
bonding (Table 1).
In humans, but not in cattle or mice, a-defensins are found
in the secretory granules of neutrophils and other leuko-
cytes.
5,6 In most mammals other than cattle, a set of a-
defensins is also produced by Paneth cells in the crypts of the
small intestine.
7,8 These a-defensins, also known as crypti-
dins, are synthesised as inactive precursors and activated by a
removal of an N-terminal segment catalysed by metallopro-
tease matrilysin (MMP7) in mice and by trypsin in hu-
mans.
9,10 After microbial stimulation, the concentration of
a-defensins within the crypts is estimated to reach 10mg/ml,
which is more than sufficient for strong microbicidal
action.
11 This, and the association of Crohn’s disease with
dysregulation in cryptidin production,
12 highlights the
importance of a-defensins in the maintenance of immune
homeostasis in the gut.
b-Defensins are expressed by most epithelial cells, and
their expression is often stimulated by proinflammatory
stimuli and infection. They are present in the mucosal
secretions of respiratory, gastrointestinal, and urogenital
tracts, and in inflamed skin.
13–16 b-Defensins are also
expressed by human monocytes, macrophages, and dendritic
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The much rarer y-defensins are cyclic molecules, produced
in neutrophils and monocytes of rhesus macaques through
ligation of two a-defensin-like peptides.
17 As a result of their
cyclic structure, the (moderate) microbicidal activity of
y-defensins is resistant to salt concentration. However,
y-defensins have not been found in humans or other
mammals.
Cathelicidins are the other major family of natural HDPs,
although they are grouped by their mechanism of produc-
tion rather than sequence similarity. All cathelicidins are
synthesised as inactive precursors, comprising an N-terminal
cathelin-like domain followed by the peptide region, and are
proteolytically processed to release mature active HDPs.
18
Cathelicidins vary in length, sequence, and structure, having
extended, a-helical or b-hairpin folds; however, some are
short linear molecules (for example, indolicidin, 13 amino
acids), and these are ideal starting points for the design of
synthetic peptides with optimised biological activity.
Bovine and porcine immune systems produce a large
variety of cathelicidins, including bactenecin, indolicidin,
PR-39, protegrins, prophenins, and many others.
18 In
contrast, in humans there is only one known cathelicidin
precursor protein hCAP18, which is proteolytically processed
to yield mature cathelicidin LL-37
19 and, in the skin, a series
of additional proteolytic derivatives with altered activities.
20
LL-37 lacks disulphide bonds and is weakly structured in
solution, but adopts an a-helical conformation when inter-
acting with lipid bilayers. Mice also have only one cathe-
licidin precursor, which is processed to produce mature
peptide CRAMP, with 67% sequence identity to LL-37.
21
LL-37 is found in the secretory granules of neutrophils and
other leukocytes,
22 and is also produced by mucosal epithelia
and keratinocytes.
23–25 The expression of LL-37 is modestly
upregulated by proinflammatory stimuli, and is also induced
by the HIF-1a and the vitamin D receptor pathways.
26–28
Many other HDPs that do not belong to the defensin or
cathelicidin families have also been characterised in humans
and other mammals. Some important examples include:
histatins, histidine-rich cationic peptides with antifungal
activity present in the saliva;
29 dermcidin, an anionic
peptide present in human sweat with modest salt-insensitive
antimicrobial properties;
30 cationic peptide lactoferricin
derived from an iron-binding protein lactoferrin and found
in mucosal secretions, milk, and in the granules of
leukocytes.
31
Biological activities and roles of host defence
peptides in immunity
The evolutionarily widespread distribution and the extreme
diversity of HDPs highlight their prominent role in immune
defences. Historically, this has been attributed to their
antimicrobial activity but in recent years potent immuno-
modulatory properties of HDPs have been characterised and
suggested to be an important part of their biological
function.
19,32 An in-depth understanding of the physiologi-
cal roles and mechanisms of action of HDPs is crucial for the
development of artificial variants with optimised activity for
therapeutic applications.
Antimicrobial properties of HDPs are linked to their
amphipathic fold, which allows the peptides to interact
with lipid bilayers of microorganisms,
2 and kill either
through membrane disruption or by translocating across
the membrane and inhibiting cytosolic targets. Owing to the
relatively nonspecific nature of the interactions between
HDPs and the anionic lipids of microbial membranes, many
peptides have broad antimicrobial properties, targeting
Gram-positive and -negative bacteria, fungi, protozoa, and
some viruses.
1,33 Furthermore, HDPs are highly effective
Table 1 The diversity of mammalian host defence peptides
Peptide family and structure Subfamily Expression and diversity
Human Mouse Pig Cow
Defensin
Amphipathic, cationic
peptides
Triple-stranded
antiparallel b-sheet
a-defensins
Three disulphide
bonds linking
cysteines 1–6,
2–4, 3–5
Neutrophils and other
leukocytes
Paneth cells of the
intestines
Mucosal epithelia, skin
Paneth cells of the
intestines
Epithelial cells
No a-defensins
b-defensins
Three disulphide
bonds linking
cysteines 1–5,
2–4, 3–6
Mucosal epithelia and skin
Monocytes,
macrophages, dendritic
cells
Epithelial cells Epithelial cells Epithelial cells
Neutrophils and
other leukocytes
Cathelicidin
Amphipathic, cationic
peptides
Diverse sequence and
structure
Cleaved from a cathelin-like
precursor protein
Non-applicable LL-37
expressed by
neutrophils, and other
leukocytes
mucosal epithelia, skin
CRAMP
expressed by
neutrophils, and
other leukocytes
mucosal epithelia,
skin
Large variety: protegrins,
PR-39, prophenins, etc.
Expressed by neutrophils
and other leukocytes
Large variety:
bactenecin, BMAP,
indolicidin, etc.
Expressed by
neutrophils and
other leukocytes
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interact with mammalian membranes and this is at least
partly responsible for cytotoxicity of some peptides at high
concentrations.
34 However, distinct composition of mamma-
lian membranes, with preferential localisation of anionic
phospholipids into the inner leaflet, offers some protection.
Furthermore, membrane interactions and antimicrobial
properties of most HDPs are strongly dependent on the
composition of the media, being inhibited by divalent cations
and serum.
19,14,34 Thus, although HDPs almost certainly
function as powerful microbicidal agents in some physiologi-
cal settings, such as the phagolysosomes of neutrophils,
intestinal crypts, and sites of acute inflammation, under other
conditions where salt concentrations are high (100mM
monovalent and 2mM divalent cations) and peptide concen-
trations are modest, their immunomodulatory activities are
almost certainly more physiologically relevant.
A wide range of HDPs from different species have been
shown to act as chemoattractants for cells of innate and
adaptive immunity. As an example, human cathelicidin
LL-37 attracts neutrophils, monocytes, Tcells, and mast cells,
using formyl peptide receptor-like 1 (FPRL1), and a distinct
Gi-coupled receptor.
35,36 Optimal chemotactic activity of
LL-37 is observed in a concentration range that can be
reached in vivo under inflammatory conditions.
35 Further-
more, synthetic peptide IDR-1, which is protective in mouse
models of bacterial infections, similarly chemoattracts
neutrophils, acting through receptor FPRL1.
37,38
Apart from direct chemotactic effects, HDPs also elicit
other complex responses in leukocytes and epithelial cells,
altering gene expression and behaviour to facilitate and to
modulate immune responses (Figure 1). For example, when
LL-37 was used to stimulate primary human monocytes and
macrophage cell lines, microarrays demonstrated the induc-
tion of a wide range of chemokines, chemokine receptors,
and other genes involved in cell adhesion, communication,
and motility.
40 In particular, induction of chemokines IL8,
Gro-a, MCP1, MIP-1b, and MIP-3a, but not proinflammatory
Figure 1 Immunomodulatory activity of host defence peptides: human cathelicidin LL-37. LL-37 induces global alterations in gene expression in monocytes,
signalling through p38, ERK, PI3K, and NF-kB pathways, and promoting expression of chemokines and other genes involved in cell communication and motility.
32,39
LL-37 also acts as a direct chemoattractant for monocytes, neutrophils, T cells, and mast cells through the FPRL1 receptor,
35 and an unknown Gi-coupled receptor.
36
LL-37 is also strongly anti-endotoxic and inhibits the production of proinflammatory cytokines in monocytes in response to LPS,
40 and also the maturation of
monocyte-derived dendritic cells by TLR ligands.
41 In contrast, LL-37 pretreatment of monocytes modulates the process of dendritic cell differentiation, enhancing
their function;
42 and in plasmacytoid dendritic cells (pDCs) LL-37 promotes responses to TLR9 ligands.
43 Other activities of LL-37 include the promotion of
antimicrobial functions of neutrophils,
44 mast cell degranulation,
45 and IL-1b processing in LPS-primed monocytes.
46 LL-37 also affects neutrophil and epithelial cell
apoptosis.
47–49 In keratinocytes, LL-37 induces IL8, and promotes migration and wound healing, and these activities depend on ADAM family metalloproteinase,
EGFR and FPRL1.
50,51 In airway epithelial cells, LL-37 activates p38 and ERK pathways and induces chemokine secretion, and this is reported to be mediated by
receptors: FPRL1,
35,52 ADAM family metalloproteinase and EGFR,
53 and through active peptide internalisation.
52 LL-37 also promotes angiogenesis, through FPRL1
receptor on vascular endothelium.
54
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and synthetic peptides.
HDPs also act as powerful modulators of cellular responses
to inflammatory stimuli. Thus, LL-37 can inhibit secretion of
inflammatory cytokines in response to lipoploysaccharide,
40
and offer some protection in experimental endotoxaemia in
mice.
32 Direct interaction with lipoploysaccharide accounts
for only a fraction of the anti-endotoxic activity of LL-37, and
transcriptional profiling of human monocytes stimulated
with lipoploysaccharide, with and without LL-37, established
a complex pattern of modulation of the lipoploysaccharide
response, with a profound inhibition of proinflammatory
genes, but retention of expression of chemotactic mediators
and negative regulators of TLR signalling.
40 On the basis of
these studies, we have proposed that at least in some
physiological settings LL-37 and possibly other peptides act
to promote localised immunity to infection, while prevent-
ing systemic hyperinflammatory response.
In contrast to the well-established anti-endotoxic activity
of some peptides, the effects of peptides on cellular responses
to other proinflammatory stimuli are cell type and stimulus
dependent. This is well illustrated by the effects of peptides
on dendritic cells. Immature monocyte-derived dendritic
cells generated in the presence of LL-37 have increased
phagocytic activity and, after maturation, show enhanced
capacity to induce Th1-polarised immunity.
42 In contrast,
simultaneous treatment of immature monocyte-derived
dendritic cells with LL-37 and TLR ligands inhibits dendritic
cell maturation.
41 In plasmacytoid dendritic cells, LL-37
strongly augments responses to host and bacterial DNA, and
this activity may contribute to the pathology of psoriasis.
43
Furthermore, murine b-defensin 2 was reported to act as an
endogenous TLR4 ligand, promoting dendritic cell matura-
tion and Th1 polarisation of immune response.
55
The biological importance of HDPs in mammalian im-
munity has been investigated in several mouse models. The
role of cryptidins in the gut is highlighted by the following
reports: MMP7-knockout mice lacking mature cryptidins and
NOD2-null mice with reduced cryptidin production are
more susceptible to oral challenges with Escherichia coli and
Listeria,
10,56 whereas transgenic mice with a Paneth cell-
specific expression of human cryptidin HD5 are more
resistant to oral challenges with Salmonella.
57 The role of
cathelicidins in the immune defences of epithelial surfaces is
addressed by the studies of CRAMP-null mice, which develop
necrotic skin infections when challenged with group A
Streptococcus,
58 and are also more susceptible to infections of
the urinary tract.
59
Dysregulation of HDP production is also implicated in the
pathology of a number of human diseases. In the specific
granule deficiency and morbus Kostmann syndromes,
deficiencies in neutrophil HDPs (and other proteins of
neutrophil granules) are associated with persistent bacterial
infections.
60,61 Reduced HDP production in the skin is also
associated with human disorders, with reduced LL-37 and
b-defensin levels in atopic dermatitis being linked to frequent
skin infections.
62 In contrast, abnormally high levels and
altered proteolytic processing of cathelicidins are implicated
in skin inflammatory conditions of rosacea and psoriasis.
43,63
Disruption of HDP production and function at mucosal
surfaces is also implicated in human pathologies, in parti-
cular in Crohn’s disease and cystic fibrosis. It was suggested
that the bacterial colonisation of the airways of cystic fibrosis
patients, is at least in part, the result of inactivation of
antimicrobial peptides by the high salt contents of airway
fluids in cystic fibrosis.
64,65 Mutations in NOD2, associated
with Crohn’s disease, result in impaired production of
cryptidins and this was proposed to contribute to the chronic
intestinal inflammation by disrupting the interactions
between the immune system and the microflora.
12,56
In summary, HDPs with their direct antimicrobial proper-
ties and diverse immunomodulatory activities play an
important role in mammalian immunity to infections and
immune homoeostasis. The potential for these activities for
clinical and commercial purposes remains to be fully
explored.
Therapeutic potential of host defence peptides
With increasing bacterial resistance to conventional anti-
biotics,
66 there is a growing interest in exploiting the
biological activities of HDPs to target multidrug-resistant
pathogens.
3 However, despite much progress in the labora-
tory, so far only a few HDP-derived compounds have
progressed into the clinic, with most clinical trials focusing
on topical rather than systemic applications (Table 2).
The traditional approach to developing HDP-based ther-
apeutics has focused on the antimicrobial properties of
natural peptides. Various methodologies for identifying,
selecting, or designing highly active artificial antimicrobial
peptides have been developed. One approach is to screen
extensive libraries of semirandom peptides for bactericidal
properties.
67,68 Alternatively, systematic substitutions in the
amino-acid sequence of natural antimicrobial HDPs can be
used to improve their activity. For example, combining high-
throughput peptide synthesis on cellulose sheets with
automated screening for antimicrobial properties using a
luciferase reporter system allowed the development of
bactenecin derivatives with dramatically improved activ-
ity.
69 Furthermore, several computer-aided approaches to
analyse structure–function relationships in natural and
artificial peptide libraries permitted the prediction of peptide
activity and design of novel peptides with stronger anti-
microbial properties.
70,71
One of the limitations that need to be overcome before
peptides can be widely used in the clinic is the high cost of
peptide production. Costs can be reduced to some extent by
focusing on linear peptides of minimal length, and truncated
derivatives of bactenecin and indolicidin with lengths
of 8–12 amino acids are good candidates.
69 However,
more complex structures can be effectively generated on a
large scale using recombinant technology
72 and should
certainly be pursued. Lantibiotics are bacterial peptides with
Host defence peptides: potential therapeutic applications Emerging Health Threats Journal
A Nijnik and REW Hancock 2009, 2:e1
www.eht-journal.org page 4/7antimicrobial properties produced on an industrial scale for
use as food preservatives. They make up one class of such
compounds.
73 Their potential therapeutic value certainly
warrants further investigation. Another approach to redu-
cing the costs of peptide therapeutics is to improve peptide
stability and pharmacokinetics, thus decreasing the required
dose. Currently, this is investigated with protease-resistant
D-amino acid peptides and various peptidomimetics.
3
Concerns have been raised that a widespread use of HDPs
in the clinic would select for pathogens resistant to natural
immune defences. Indeed, many bacterial species already
possess modestly effective resistance mechanisms, including
peptide degradation, sequestration, efflux, and chemical
modifications of cell walls and membranes to reduce HDP
binding;
74,75 resistance to HDPs can be selected in the
laboratory.
76 Nevertheless, HDPs are less prone to inducing
resistance than conventional antibiotics because they often
use several microbicidal mechanisms simultaneously, target-
ing many microbial systems with low affinity rather than
having one specific target.
75 Also, because of the diverse
mechanisms of peptide action, the use of synthetic peptides
that do not occur in nature could partly alleviate the
problem of resistance to natural HDPs. Finally, immuno-
modulatory peptides that act on the host rather than on the
pathogen offer a unique opportunity to minimise the direct
selective pressures for pathogen resistance.
Recently, such an immunomodulatory peptide, an innate
defence regulator IDR-1, was shown to protect mice against
bacterial infections, including infections with multidrug-
resistant pathogens, and this provides an important proof of
principle for the immunomodulatory approach.
38 The pep-
tide was shown to act as a neutrophil chemoattractant
37 and
furthermore to induce chemokine production and promote
cell recruitment in vitro and in vivo; these activities may
account for some of its protective effects. Importantly this
peptide, as well as many natural HDPs, exerts anti-inflam-
matory and anti-endotoxic effects at the same time as
promoting local clearance of infection.
38,40 Thus, unlike
other treatments aimed at boosting the immune system,
such peptides can offer protection without the risk of
inducing dangerous hyperinflammatory states. In the
immediate future, the field of immunomodulatory peptide
therapeutics faces the challenges of developing high-
throughput screens for immunomodulatory activity, and
also of firmly defining which in vitro activities correlate with
the protection against infection and other desirable biologi-
cal outcomes in vivo. Furthermore, other activities of HDPs,
such as their roles in wound healing and angiogenesis,
require further investigation to assess their potential ther-
apeutic value.
54
Conclusion
Over the course of evolution, nature has created an
impressive arsenal of HDPs with extreme diversity in
structure and biological activity. These can serve as excellent
templates for development of both antimicrobial and
immunomodulatory compounds, often combining both
activities in the same molecule. The potential therapeutic
value of such compounds is just beginning to be fully
recognised. These compounds can be used in combination
with conventional antibiotics, and also to target resistant
pathogens where conventional antibiotics fail. Some pep-
tides may even have potential against diseases of unknown
aetiology (emerging infectious diseases), as their spectrum of
activity is often very broad and may involve stimulation of
the immune response of the host rather than targeting the
pathogen. Importantly, immunomodulatory peptides that
target the host immune system rather than the pathogen
also offer an excellent opportunity to minimise the risks of
pathogen resistance to these compounds. The current
challenge is to develop new biologically active synthetic
peptides or mimetics thereof with improved pharmacoki-
netics, low toxicity, and low manufacturing costs for both
topical and systemic applications.
Table 2 Peptides and peptidomimetics in commercial development
Company Drug Stage of
development
Medical use
AM-Pharma (Bunnik, The Netherlands) hLF-1-11 Phase II Allogeneic bone marrow stem cell transplantation-associated infections
BioLineRx Ltd (Jerusalem, Israel) BL2060 Preclinical Gram-negative pneumonia
Ceragenix (Denver, Colorado, USA) CSA-13
a/CGX313 Preclinical Prevention of nasal carriage of Staphylococcus
Helix Biomedix (Bothell, Washington, USA) Lipohexapeptide Preclinical Anti-infective
Inimex (Burnaby, British Columbia, Canada) IMX942 Preclinical Immunomodulation; treatment of fevers and neutropaenia
in chemotherapy patients
Migenix Inc. (Vancouver, British Columbia, Canada) CPI/MX-226 Phase IIIb Prevention of catheter-related infections
CLS001 Phase II+ Inflammation in Rosacea
Novozymes A/S (Bagsvaerd, Denmark) Plectasin Preclinical Systemic anti-Gram positive, especially pneumococcal infections
Pacgen (Vancouver, British Columbia, Canada) PAC113 Phase IIb Oral candidiasis
Polymedix (Radnor, Philedelphia, USA) PMX30063
b Phase I Systemic anti-infective peptidomimetic
aA cationic steroid antibiotic.
bNon-peptidic structural analogue of an antimicrobial peptide.
This is a listing of known antimicrobial and/or immunomodulatory agents in development and/or clinical trials within private companies. Only agents currently in
clinical trials or likely to enter the clinic soon are recorded. This information is based on a prior review,
3 updated by us primarily from company press releases and
public presentations. Several peptides that went through clinical trials but were not approved
3 or polymyxins and gramicidin S that are generic anti-infectives that
have long been available are not described.
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